-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Time flies, and it is about to enter May in the blink of an eye
.
The author found that in the past half a year since the beginning of January 2021, "grouping" among pharmaceutical companies has become the norm.
Among them, since April only, there have been news of cooperation from many pharmaceutical companies
.
This article makes a brief inventory of the recent pharmaceutical-enterprise cooperation cases that have attracted more attention in the industry
.
Aide Bio & AstraZeneca: Achieving Targeted Drug Clinical Research Cooperation On April 18, Aide Bio announced that the company and AstraZeneca signed two cooperation agreements
.
First, the company will work with AstraZeneca to promote the company's self-developed companion diagnostic products for the registration of companion diagnostics for prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union and Japan; second, the company Will work with AstraZeneca to advance another companion diagnostic product independently developed by the company for the registration of companion diagnostics for breast cancer patients with BRCA mutations in the European region
.
Aide Bio & Chi-Med: Achieving Targeted Drug Clinical Research Cooperation On April 7, Aide Bio announced that it has reached a targeted drug clinical research cooperation with Chi-Med, and the company will work with Chi-Med to jointly promote the company in the Chinese market.
The self-developed companion diagnostic reagent is registered in the companion diagnosis of the combination therapy of sivotinib and osimertinib mesylate tablets for the treatment of non-small cell lung cancer
.
Regeneron & SpringWorks: Collaboration on Multiple Myeloma Therapy Recently, Regeneron announced the decision to acquire Checkmate Pharmaceuticals, and also said that it is collaborating with SpringWorks Therapeutics on a clinical trial to evaluate the therapeutic effect of REGEN5458 in combination with nirogacestat
.
Under the collaboration agreement, Regeneron will be responsible for clinical development and cover all costs associated with the study, except those associated with nirogacestat
.
It is understood that nirogacestat is an investigational, oral, selective small molecule gamma-secretase inhibitor in Phase III clinical development trials for noncancerous growths in desmoid tumors that occur in connective tissue
.
SpringWorks also noted in preclinical models that nirogacestat has been shown to increase levels of membrane-bound B cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells, thereby enhancing BCMA-targeting activity
.
Harmonicare & AstraZeneca: Collaboration on the Development and Commercialization of CLDN18.
2xCD3 Bispecific Antibody Recently, Harmonicare announced that the company and AstraZeneca will cooperate on the development and commercialization of CLDN18.
2xCD3 bispecific antibody (HBM7022).
Reached a global external licensing agreement
.
Under the agreement, AstraZeneca will receive an exclusive worldwide license for the research, development, registration, manufacturing and commercialization of HBM7022, and will be responsible for all costs associated with further preclinical development and commercialization of HBM7022
.
Harbin Pharmaceutical will receive an upfront payment of $25 million and milestone payments of up to $325 million, as well as royalties based on future sales of HBM7022
.
On April 7, Genting Xinyao announced that the company and China Resources Pharma signed a memorandum of cooperation to establish an independent company focusing on the discovery, development and commercialization of mRNA vaccines
.
Genting Xinyao said that through cooperation with China Resources Pharma in the fields of registration and commercialization, it will gain advantages for the further development of mRNA company and promote the development progress of Genting Xinyao's best-in-class mRNA vaccine candidates in China
.
Yuanxin Technology & Shengfang Pharmaceutical: The two parties will carry out in-depth cooperation in real-world research and other fields.
On April 6, Yuanxin Technology and Shengfang Pharmaceutical R&D announced that they have reached a strategic cooperation agreement.
.
According to the agreement, the two parties will carry out in-depth cooperation in real-world research and other fields.
The two parties will give full play to their respective advantages and provide more clinical research and decision-making support for medical institutions and pharmaceutical companies by integrating the pharmaceutical service supply chain capabilities with real-world research.
Dimensional high-value data analysis support further enriches clinical research methods, improves decision-making level, accelerates the process of new drug research and development and achievement transformation, and contributes to the high-quality development of the industry
.
Wanfu Bio & General Technology China Pharmaceutical: Signed a Strategic Cooperation Agreement on Antigen Detection Reagent Products On April 1, General Technology China Medical and Health Industry Co.
, Ltd.
announced the signing of a strategic cooperation agreement with Wanfu Biotechnology.
The two parties will focus on the marketing of antigen detection reagent products.
, medical device business, project promotion, international trade and other business cooperation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The author found that in the past half a year since the beginning of January 2021, "grouping" among pharmaceutical companies has become the norm.
Among them, since April only, there have been news of cooperation from many pharmaceutical companies
.
This article makes a brief inventory of the recent pharmaceutical-enterprise cooperation cases that have attracted more attention in the industry
.
Aide Bio & AstraZeneca: Achieving Targeted Drug Clinical Research Cooperation On April 18, Aide Bio announced that the company and AstraZeneca signed two cooperation agreements
.
First, the company will work with AstraZeneca to promote the company's self-developed companion diagnostic products for the registration of companion diagnostics for prostate cancer patients with homologous recombination repair (HRR) gene mutations in China, the European Union and Japan; second, the company Will work with AstraZeneca to advance another companion diagnostic product independently developed by the company for the registration of companion diagnostics for breast cancer patients with BRCA mutations in the European region
.
Aide Bio & Chi-Med: Achieving Targeted Drug Clinical Research Cooperation On April 7, Aide Bio announced that it has reached a targeted drug clinical research cooperation with Chi-Med, and the company will work with Chi-Med to jointly promote the company in the Chinese market.
The self-developed companion diagnostic reagent is registered in the companion diagnosis of the combination therapy of sivotinib and osimertinib mesylate tablets for the treatment of non-small cell lung cancer
.
Regeneron & SpringWorks: Collaboration on Multiple Myeloma Therapy Recently, Regeneron announced the decision to acquire Checkmate Pharmaceuticals, and also said that it is collaborating with SpringWorks Therapeutics on a clinical trial to evaluate the therapeutic effect of REGEN5458 in combination with nirogacestat
.
Under the collaboration agreement, Regeneron will be responsible for clinical development and cover all costs associated with the study, except those associated with nirogacestat
.
It is understood that nirogacestat is an investigational, oral, selective small molecule gamma-secretase inhibitor in Phase III clinical development trials for noncancerous growths in desmoid tumors that occur in connective tissue
.
SpringWorks also noted in preclinical models that nirogacestat has been shown to increase levels of membrane-bound B cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells, thereby enhancing BCMA-targeting activity
.
Harmonicare & AstraZeneca: Collaboration on the Development and Commercialization of CLDN18.
2xCD3 Bispecific Antibody Recently, Harmonicare announced that the company and AstraZeneca will cooperate on the development and commercialization of CLDN18.
2xCD3 bispecific antibody (HBM7022).
Reached a global external licensing agreement
.
Under the agreement, AstraZeneca will receive an exclusive worldwide license for the research, development, registration, manufacturing and commercialization of HBM7022, and will be responsible for all costs associated with further preclinical development and commercialization of HBM7022
.
Harbin Pharmaceutical will receive an upfront payment of $25 million and milestone payments of up to $325 million, as well as royalties based on future sales of HBM7022
.
On April 7, Genting Xinyao announced that the company and China Resources Pharma signed a memorandum of cooperation to establish an independent company focusing on the discovery, development and commercialization of mRNA vaccines
.
Genting Xinyao said that through cooperation with China Resources Pharma in the fields of registration and commercialization, it will gain advantages for the further development of mRNA company and promote the development progress of Genting Xinyao's best-in-class mRNA vaccine candidates in China
.
Yuanxin Technology & Shengfang Pharmaceutical: The two parties will carry out in-depth cooperation in real-world research and other fields.
On April 6, Yuanxin Technology and Shengfang Pharmaceutical R&D announced that they have reached a strategic cooperation agreement.
.
According to the agreement, the two parties will carry out in-depth cooperation in real-world research and other fields.
The two parties will give full play to their respective advantages and provide more clinical research and decision-making support for medical institutions and pharmaceutical companies by integrating the pharmaceutical service supply chain capabilities with real-world research.
Dimensional high-value data analysis support further enriches clinical research methods, improves decision-making level, accelerates the process of new drug research and development and achievement transformation, and contributes to the high-quality development of the industry
.
Wanfu Bio & General Technology China Pharmaceutical: Signed a Strategic Cooperation Agreement on Antigen Detection Reagent Products On April 1, General Technology China Medical and Health Industry Co.
, Ltd.
announced the signing of a strategic cooperation agreement with Wanfu Biotechnology.
The two parties will focus on the marketing of antigen detection reagent products.
, medical device business, project promotion, international trade and other business cooperation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
